London — The Covid-19 vaccine, being developed by the University of Oxford and AstraZeneca PLC, was found in a large clinical trial to be 90% effective in preventing infection without serious side effects, partners said Monday. Said to.
AstraZeneca said there were no significant safety events associated with the vaccine and it was well tolerated across various dosing regimens. Efficacy ranged from 62% to 90%, depending on the dose given, the partner said. AstraZeneca and Oxford stated that the average validity of the analysis was 70%.
The exam was held in the UK and Brazil. Late clinical trials of the vaccine are continuing in the United States after a clinical trial suspension that spans most of September and October.
This result was developed by Moderna Inc. and developed by Pfizer Inc. And Germany’s BioNTech SE jointly developed a shot that proved to be more than 90% effective late in the day, a precursor to the final availability of a third Western-developed vaccine to combat Covid-19. Stage trial.
Pfizer and BioNTech said late last week that they sought approval from the US Food and Drug Administration to authorize the use of the vaccine.
AstraZeneca, Oxford Covid-19 vaccine up to 90% effective in late-stage trials
Source link AstraZeneca, Oxford Covid-19 vaccine up to 90% effective in late-stage trials